Clinical Trial Update: Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating intratumoral CpG-ODN injections to boost immune killing and in situ tumor antigen release in advanced solid tumors, currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Lung Cancer

Drugs mentioned

• Intratumor CpG-ODN injection (CpG oligodeoxynucleotide)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Lung Cancer, Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING